Healthcare

Meet your Healthcare Research team

Clinigen

FY 2020 results: stock now looks materially mispriced

Today’s FY 2020 results reaffirmed the strong underlying growth indicated at the year-end trading update in July. Much improved working capital dynamics in H2 boosted cash conversion....

Amryt Pharma

Filsuvez – Phase III success; pathway opened for commercial launch; increasing price target

Filsuvez achieving the primary endpoint in its Phase III trial for epidermolysis bullosa (EB) now makes drug approval highly likely and opens the pathway for commercialisation. It could be...

Malin Corporation

Compelling Kymab data; Malin increases stake

Kymab’s compelling phase 2a data for its potentially market leading eczema drug are indicative of the momentum building in Malin’s priority asset base following Poseida’s IPO in July. Malin...

Uniphar

Expanding access

The Uniphar investment case is rapidly transitioning from ‘value’ to ‘growth’. A key part of the growth agenda is driven by Product Access, in particular Expanded Access Programs...

Amryt Pharma

Momentum continues to build

Amryt’s Q2 results indicate good momentum in all aspects of the business. Growth in its commercial portfolio continues to be robust despite COVID-19, as evidenced by the company issuing...

UDG Healthcare plc

Q3 IMS: sharpening the focus

Sharp is the highlight of today’s trading update, both in terms of Q3 performance and capital deployment. The $37.5m Berkshire Sterile Manufacturing (BSM) investment is an excellent...

Clinigen

COVID-19 and Foscavir headwinds tarnish outlook

COVID-19 aside, FY 20 looks like a strong year of growth for Clinigen, with good underlying performances called out across the three divisions. Improving cash flow dynamics boosted cash...

Malin Corporation

Poseida IPO – priced at top of its range

The pricing of Poseida’s IPO at the top end of its range at $16 and the increase in the share offering to 14m are indicative of the healthy demand in the IPO. Based on the pricing, the...

Malin Corporation

Poseida - $110m financing round

We think today’s Series D funding round, led by Fidelity Management Research Company (FMR), is supportive of Poseida’s potential near-term IPO. Malin has not participated in this round...

Malin Corporation

Poseida files for IPO of up to $115m

With Poseida filing for IPO on NASDAQ, Malin is one step closer to crystallising value in this key priority asset. The IPO could become effective mid-late July. Recent IPO activity suggests...